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Abstract
Cancer stem cells (CSCs) are capable of continuous proliferation and self-renewal and are proposed to play significant roles
in oncogenesis, tumor growth, metastasis and cancer recurrence. CSCs are considered derived from normal stem cells
affected by the tumor microenvironment although the mechanism of development is not clear yet. In 2007, Yamanaka’s
group succeeded in generating Nanog mouse induced pluripotent stem (miPS) cells, in which green fluorescent protein
(GFP) has been inserted into the 59-untranslated region of the Nanog gene. Usually, iPS cells, just like embryonic stem cells,
are considered to be induced into progenitor cells, which differentiate into various normal phenotypes depending on the
normal niche. We hypothesized that CSCs could be derived from Nanog miPS cells in the conditioned culture medium of
cancer cell lines, which is a mimic of carcinoma microenvironment. As a result, the Nanog miPS cells treated with the
conditioned medium of mouse Lewis lung carcinoma acquired characteristics of CSCs, in that they formed spheroids
expressing GFP in suspension culture, and had a high tumorigenicity in Balb/c nude mice exhibiting angiogenesis in vivo. In
addition, these iPS-derived CSCs had a capacity of self-renewal and expressed the marker genes, Nanog, Rex1, Eras, Esg1 and
Cripto, associated with stem cell properties and an undifferentiated state. Thus we concluded that a model of CSCs was
originally developed from miPS cells and proposed the conditioned culture medium of cancer cell lines might perform as
niche for producing CSCs. The model of CSCs and the procedure of their establishment will help study the genetic
alterations and the secreted factors in the tumor microenvironment which convert miPS cells to CSCs. Furthermore, the
identification of potentially bona fide markers of CSCs, which will help the development of novel anti-cancer therapies,
might be possible though the CSC model.
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Introduction
A number of studies have attempted to identify the mechanisms
underlying malignant tumor growth and progression. Despite
significant progress, most therapeutic approaches fail to eliminate
all tumor cells. The remaining tumor cells often result in
recurrence and metastasis. Recently, the hypothesis of cancer
stem cells (CSCs) was proposed to explain the origin of cancer
cells. By definition, CSCs are a small fraction of tumor cells with
the capacity of both self-renewal and unlimited slow proliferation.
They are often resistant to chemotherapy and radiation and thus
are responsible for continuously supplying new cancer cells [1]. A
current view of the CSCs model is considered that adult stem cells,
progenitor cells, or differentiated cells may acquire the multiple
genetic and epigenetic alterations required to become CSCs that
are involved in promoting and maintaining oncogenesis. This
cancer-initiating cell may share some characteristics with adult
stem cells residing in the organ, in which they arise, either because
organs and tissues originate from resident stem cells or because
stem cells are clustered by the properties of their niche [2]. In this
context, tumor cells can be epigenetically reverted to tissue specific
stem cells when transplanted into a normal stem cell niche [3–6].
It is well known that the microenvironment can exert profound
genetic or epigenetic effects on stem cells through interactions
between cells, or through cell-derived factors originating from the
surrounding cells within the niche. These effects can be transient,
as seen in the activation of signaling pathways regulating cellular
proliferation and migration, or they can be associated with more
stable alterations, such as cell fate determination and differenti-
ation [7]. Given the critical role of the microenvironment in
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the embryonic stem cell microenvironment could have significant
influence on the phenotypic characteristics of aggressive cancer
cells [8–10]. However, as to whether the tumorigenic microenvi-
ronment can affect the fate of stem cells has not been sufficiently
explored.
In 2007, Yamanaka’s group [11] succeeded in generating Nanog
miPS cells by retroviral transduction of four transcription factors
(octamer 3/4 (Oct 3/4), SRY box-containing gene 2 (Sox2), Kruppel-like
factor 4 (Klf4) and C-myc) into mouse embryonic fibroblasts (MEF).
GFP was stably expressed in these cells, but GFP expression was
extinguished when these cells were induced to differentiate. To
date, miPS cells have been successfully differentiated into various
cell types, including hematopoietic and endothelial cells [12],
neural cells [13], cardiac cells [14] and pancreatic b-cells [15].
Despite these successful reports of in vitro differentiation, iPS cells
are not entirely suitable for transplantation into patients. The main
issue is safety concerns in that iPS cells tend to form teratomas and
have a risk of malignant transformation [16–18]. Based on the
CSCs theory, we ascertained whether CSCs can be derived from
miPS cells after exposure to a tumor microenvironment (Fig. 1).
Results
The miPS cells cultured in the conditioned media of
cancer cell lines showed tumorigenicity and angiogensis
in vivo
In this study, we designed two procedures to treat miPS cells.
miPS cells were cultured without feeder cells in a mixture of miPS
medium and conditioned medium obtained from the following
mouse cancer cell lines: Lewis lung carcinoma (LLC), mouse
embryonal carcinoma (P19), mouse melanoma (B16) and mouse
mammary carcinoma (MC.E12) for 4 weeks. miPS cells cultured
under these conditions were termed miPS-LLCcm, miPS-P19 cm,
miPS-B16 cm, and miPS-MC.E12 cm cells respectively. miPS
cells were also cocultured with each cancer cell line that had
previously been treated with mitomycin C as feeder cells for
4 weeks. These miPS cells were termed miPS-LLCc, miPS-P19c,
miPS-B16c and miPS-MC.E12c cells respectively. The miPS cells
that had been cultured with or without feeder cells under the
different conditions were then transplanted into nude mice. After
4 weeks, miPS cells formed typical teratomas that contained
differentiated tissues without metastasis (Fig. S1A). In contrast,
mouse allografts of miPS cells that had been treated with
conditioned media, miPS-LLCcm, miPS-P19 cm, miPS-B16 cm
and miPS-MC.E12 cm cells, formed undifferentiated carcinomas
that possessed cells with high nuclear to cytoplasmic ratio, nuclear
pleomorphism, aberrantly high mitotic rates, and multiple
pathological mitotic figures (Fig. 2A and S1B). On the other
hand, only miPS-MC.E12c cells in the coculture group formed
malignant tumors (Fig. S1B). The tumorigenicity of the different
cells is summarized in Table 1. It is noteworthy that only tumors
which were derived from miPS-LLCcm cells showed features of
angiogenesis and micrometastases (Fig. 2A).
The miPS-LLCcm cells had a capacity of self-renewal
Thirty to fifty percent of the cells were GFP positive in the
tumors derived from miPS-LLCcm cells while less than five
percent were positive in the differentiated teratoma (Fig. S2).
Since GFP was designed under Nanog promoter to stably express
only in cells which were undifferentiated and would be silenced in
differentiated tissues [11], most of miPS cells were considered to
be differentiated in the teratomas. On the other hand, the
malignant tissues implied to contain undifferentiated stem-like
cells. Primary cultures of the tumor should be an effective method
to potentially eliminate the differentiated cells in order to obtain
more stem-like cells derived from miPS-LLCcm. Thus the tumor
tissue derived from miPS-LLCcm cells was subjected to primary
culture, from which two distinct types of cell populations were
observed. One was stem-like cells that expressed GFP, while the
other population was fibroblast-like cells that failed to express
GFP (Fig. 2B). Since malignant cells with stem-like properties can
be propagated in vitro as nonadherent spheres [19,20], the cells
were transferred to non-adherent culture dishes to facilitate the
growth of spheroids. In suspension, GFP expression (Fig. 2B) was
observed in these tumor spheres, whereas the fibroblast-like cells
could not survive without adhesion to the bottom of dish and was
GFP negative. The spheroids derived from miPS-LLCcm tumor
Figure 1. The hypothesis of miPS differentiation when exposed to normal or malignant niche. miPS cells should be induced to some
kinds of progenitor cells, such as hematopoietic cells and neural stem cells, differentiating into various phenotypes, such as macrophage, monocytes,
neural cells, cardiac cells and pancreatic b- cells, when exposed to the normal niche. We hypothesized that CSCs may also be derived from miPS cells
only when exposure to a malignant niche.
doi:10.1371/journal.pone.0033544.g001
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forming spheroids under nonadherent condition. Indivisual cells
from dissociated spheres were able to form new spheres during
serial passage in tissue culture, demonstrating that the cells could
self-renew [21]. The tumor spheres were then transferred to
adherent culture dishes (Fig. 2B) and were subjected to
immunofluorescent staining for Nanog and Oct 3/4 (Fig. 2C).
The positive staining of Nanog and Oct 3/4, which are critical
factors to sustain the undifferentiated state and self-renewal of
stem cells [11,21], confirmed the expression of the stem cell
markers in these spheroids. An aspect of cancerous state of miPS-
LLCcm spheroid cells was addressed to the expression of p53 gene
by RT-qPCR. As the result, the expression was found downreg-
ulated to the level in LLC cancer cells (Fig. 2D). This
downregulation may indicate the malignancy of the cells. To
evaluate the tumorigenicity of the cells within the tumor spheres,
1610,4610
6 of these cells were subcutaneously transplanted into
nude mice (Table 2). After 4 weeks, tumors formed and exhibited
extensive angiogenesis (Fig. 3A), which was similar to the miPS-
LLCcm derived tumors. However, these tumors appeared more
aggressive due to the high growth rate. To examine the metastatic
potential, 1610
5 spheroid cells were injected into the mouse tail
vein. One month later, multiple metastatic nodules expressing
GFP were found in lungs showing that they were derived from
spheroid cells (Fig. 3B and 3C). And the expression level of MMP-
2 was found significantly upregulated in the spheroid cells derived
from miPS-LLCcm cells lung metastatic tumor (miPS-LLCcm
LMT spheroid) (Fig. 2D), which implied that miPS-LLCcm cells
possess the metastatic potential caused by induction of MMP-2
expression, and the population of highly metastatic cells could be
isolated from miPS-LLCcm cells through in vivo panning.
Figure 2. Characterization of miPS-LLCcm cells and derived tumor. (A) Histology of miPS-LLCcm cells derived tumor. The tumor exhibited
malignant phenotype with glandular epithelial hyperplasia (asterisk), high nuclear to cytoplasmic ratio, severe nuclear atypia and multiple
pathological mitotic figures (arrowheads, inset) (top left); micrometastases (arrow, top right); and hypervascularization indicative of angiogenesis
(bottom left) by HE staining. The positive of CD31 (Rat monoclonal antibody, brown) by IHC staining showed multiple vascular vessels in the tumor
(bottom right). Scale bars: 100 mm (top left and bottom), 50 mm (top right). (B) Primary culture derived from miPS-LLCcm tumor. The primary culture
exhibited stem-like cells (asterisk in top left) expressing GFP (top right) and fibroblast-like cells (arrow in top left) without GFP expression (top right).
Spheroid cells grown from the primary culture in suspension (middle left) with GFP expression (middle right). The spheroid cells were placed back in
adherent culture maintained stem-like cells (asterisk in bottom left) with GFP expression (bottom right) and fibroblast-like cells (arrow in bottom left)
without GFP expression (bottom right). (C) Immunofluorescence staining for Nanog and Oct 3/4 in spheroid cells. Cryosections of spheroid cells were
stained with primary antibodies (Rabbit anti-Nanog or Mouse anti-Oct-3/4) followed by anti-Rabbit or anti-mouse secondary antibodies labeled with
Alexa fluorophores 555 (red) or 488 (Green). The cells were counterstained with DAPI (blue). Scale bars: 20 mm. (D) The expression levels of p53, MMP-
2 and MMP-9 were analyzed by quantitative real-time PCR. miPS+LIF/2MEF, miPS cells cultured with LIF in the medium but without MEFfeeder cells;
miPS-LLCcm spheroid, the spheroid cells derived form miPS-LLCcm cells; miPS-LLCcm LMT spheroid, the spheroid cells derived from miPS-LLCcm cells
lung metastatic tumor; LLC, Lewis lung carcinoma cells.
doi:10.1371/journal.pone.0033544.g002
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Cell names
a Cell number Tumor formation Histologic examination
miPS (with feeder cells) 4610
6 3/3 Teratoma
miPS (without feeder cells) 4610
6 3/3 Teratoma
miPS-LLCcm cells 4610
6 8/8 Malignant tumor, angiogenesis
miPS-LLCc cells –
b
miPS-P19 cm cells 4610
6 5/5 Malignant tumor
miPS-P19c cells 4610
6 0/3
miPS-B16 cm cells 4610
6 3/5 Malignant tumor
miPS-B16c cells 4610
6 0/3
miPS-MC.E12 cm cells 4610
6 3/3 Malignant tumor
miPS-MC.E12c cells 4610
6 4/5 Malignant tumor
a: miPS cells were named with each name of cancer derived cells and ‘‘c’’ or ‘‘cm’’. ‘‘c’’ stands for the miPS cells were cocultured with mouse cancer derived cells treated
with mitomycin C and ‘‘cm’’ for the miPS cells cultured in the conditioned medium of cancer derived cells.
b: Cells could not survive after several passages in subculture.
doi:10.1371/journal.pone.0033544.t001
Figure 3. Characterization of tumor derived from spheroid cells. (A) Histology of tumor derived from spheroid cells. The tumor showed some
glandular structure (asterisks) with multiple pathologic mitotic figures (arrowheads, inset) (left), high mitotic rates (arrowheads in middle), and
hypervascularization (right) by HE staining. Scale bars: 100 mm. (B) Lung metastasis after tail vein injection of spheroid cells. Lungs were occupied by
metastatic tumor nodules. (C) The metastases showed some glandular structure (asterisks) with multiple pathologic mitotic figures (arrowheads in
top left); hypervascularization (top right); invasion into lung parenchymal tissue (bottom left) by HE staining. The expression of GFP (Rabbit polyclonal
antibody, brown) was found in these metastatic nodules by IHC staining (bottom right). T, tumor; L, lung tissue. Scale bars: 100 mm. (D)
Immunohistochemistry of CK and GFP localization in tumors derived from miPS, miPS-LLCcm and spheroid cells. Serial sections were stained with CK
(mouse monoclonal antibody, brown) and GFP (Rabbit polyclonal antibody, brown), and counterstained with hematoxylin. Glandular region were CK
positive but GFP negative in the tumors. Scale bars: 100 mm.
doi:10.1371/journal.pone.0033544.g003
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composed of adenocarcinomas and abundant
undifferentiated tumor cells
We then investigated the type of the malignant tumor by IHC.
Pan-Cytokeratin (CK, an epithelial tumor cells marker), vimentin
(a marker of mesenchymal tumor), a-actin (a marker of myogenic
tumor), CD31 (a marker for vasculogenesis), NF-M and GFAP
(markers of neurogenic tumor) were used to stain the tumors (data
not shown). CK was found to be strongly stained in the tumors.
The expression of CK and GFP was then assessed in multiple
serial sections. Glandular regions were CK positive but these cells
were GFP negative in the tumors (Fig. 3D). Thirty to fifty percent
of the tumor cells were GFP positive in the tumors that had been
derived from both miPS-LLCcm cells and primary spheroid cells
while no regions were GFP positive in the teratoma. Therefore,
these tumors were judged adenocarcinomas mixed with abundant
undifferentiated tumor cells.
The derived cells expressed the embryonic stem cell
markers
Embryonic stem cell markers and the four transcription factors
that were transduced were then checked by reverse transcription
PCR (RT-PCR) and quantitative real-time PCR (RT-qPCR).
miPS-LLCcm cells and spheroid cells showed expression of the
embryonic stem cell markers (Fig. 4A), but expression levels were
somewhat different between these tumor cells and the original
miPS cells (Fig. 4C). Specifically, by RT-qPCR Nanog and Rex1
were significantly elevated in the miPS-LLCcm tumor cells, in
primary cultures derived from these tumors or in the spheroid
cultures as compared to the miPS cells grown in the absence or
presence of feeder cells. In contrast, the expression of the four
transcription factors was found to be decreased in varying degree
in both miPS-LLCcm cells and spheroid cells as compared to the
miPS cells that were propagated on feeder cells (Fig. 4B and 4D).
Discussion
The miPS-LLCcm cells showed spheroid formation in suspen-
sion culture, a high tumorigenic potential at limited dilutions and a
high metastatic potential, which were all consistent with the basic
characteristics of CSCs [19,22,23]. Rapid tumor growth requires
de novo angiogenesis in which the vascular niche provides growth-
promoting signals. The tumors derived from miPS-LLCcm cells
including the spheroid cells also showed a high degree of
angiogenesis, which was not observed in the teratomas derived
from miPS cells. The close association of CSCs and blood vessels
has earlier been documented in the nervous system and these
vascular niches assist in the maintenance of CSCs [24]. IFNc,a
major negative regulatory molecule of angiogenesis, has been
shown to down-regulate the expression of MMPs, inhibit
endothelial cell migration as well as induce the angiostatic factor
IP-10 through activate of JAK-STAT signal pathway [25].
Microarray assessment comparing the miPS cells and miPS-
LLCcm cells showed down-regulation of IFNcR in miPS-LLCcm
cells (Materials and Methods S1, Table S1), which might be
responsible for the angiogenesis in miPS-LLCcm cells derived
tumor. Higher expression of MMP-2 in miPS-LLCcm LMT cells
giving the metastatic potential to miPS-LLCcm cells might be a
result of IFNcR reduction, although further analysis are required.
Taking the downregulation of MMP-9 gene expression in both
miPS-LLCcm and miPS-LLCcm LMT cells into consideration,
MMP-2 appears responsible for the angiogenesis and metastasis in
this study.
Self-renewal is frequently cited as a characteristic of CSCs.
However, there are technical limitations to strictly evaluate self-
renewal. For normal tissue stem cells, the standard test of self-
renewal requires the clonal in vivo demonstration of self-renewal
and multi-lineage differentiation in primary transplants of stem
cells, followed by demonstration of the same properties in serial
transplants of the same cells. Self-renewal in tumorigenic cancer
cells has generally been evaluated by the demonstration of serial
transplantability of polyclonal tumors and by the demonstration of
a similar phenotypic heterogeneity in the parental and progeny
tumor xenografts [26]. The sequence of experiments using miPS-
LLCcm cells that were derived from primary tumors and their
repeated subculture as spheroids demonstrated the capacity of self-
renewal in the miPS-LLCcm cells obtaining secondary tumors
exhibiting the same histology and phenotype as the primary
tumors [21].
Moreover, Nanog, a marker widely associated with ‘stemness’
was still expressed at higher levels in the miPS-LLCcm cells and
spheroid cells compared to the miPS cells. Nodal and Cripto1 are
embryonic morphogens that are responsible for the maintaince of
pluripotency/self-renewal in embryonic stem cells and perform a
critical role in maintaining the undifferentiated state of cells [7]. In
miPS-LLCcm cells, Nodal and Cripto1 expression levels were
significantly higher as compared with miPS cells, which confirmed
the relatively undifferentiated state of the miPS-LLCcm cells. The
decrease of Nodal expression by 70% in spheroid cells probably
demonstrated the differentiation of spheroid cells from pluripotent
stem cells to unipotent stem cells as CSCs. A significant down-
regulation of stem cell markers was observed in teratomas that
were derived from miPS cells as these tumors contain mixed
populations of different differentiated cell types. In contrast, in
tumors derived from miPS-LLCcm cells and spheroid cells, the
expression levels of these markers also decreased but remained
much higher than those in teratomas. These results, which were
consistent with those of IHC, imply that there was a certain
amount of the CSCs in the malignant tumors while almost all of
the cells were differentiated in the teratomas.
The tumor cells developed in this study from miPS cells grew as
spheroids in suspension culture, showed a high tumorigenic and
metastatic potential and angiogenesis in vivo. In addition, the
capacity for self-renewal and maintainance of an undifferentiated
state as assessed by the expression of markers that are associated
with embryonic stem cells suggest that these primary miPS-
LLCcm cells and the spheroid cells which were derived from
miPS-LLCcm cells contain a high proportion of CSCs. Scaffidi
and Misteli have recently reported the production of CSC-like
Table 2. Summary of tumorigenic potential of miPS-LLCcm
spheroid cells.
Cell number Tumor formation Histologic examination
1610 0/4 NA
1610
2 0/4 NA
1610
3 0/4 NA
1610
4 0/4 NA
1610
5 2/4 Malignant tumor, angiogenesis
8610
5 4/4 Malignant tumor, angiogenesis
2610
6 4/4 Malignant tumor, angiogenesis
4610
6 4/4 Malignant tumor, angiogenesis
NA: not applicable.
doi:10.1371/journal.pone.0033544.t002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33544Figure 4. Gene expression in miPS cells, derived cells, MEF cells and tumor tissues. (A) RT-PCR analysis of embryonic stem cell marker gene
expression. (B) RT-PCR analysis of the four miPS transcription factors. The PCR products were the coding regions (Total), endogenous transcripts only
(Endo.), and transgene transcripts only (tg). (C) Expression levels of embryonic stem cell marker gene were analyzed by quantitative real-time PCR. (D)
Expression levels of the four miPS cell transcription factors were analyzed by quantitative real-time PCR.
doi:10.1371/journal.pone.0033544.g004
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[27]. They transduced oncogenic genes of hTERT, H-Ras V12
and SV40 T antigens to produce CSC-like cells by reprogram-
ming. It should be noteworthy that our CSC model was developed
without using gene transduction. This is the first report to
demonstrate the development of a CSCs population from miPS
cells that can be achieved by factors which are secreted by tumor
cells although the identity of these soluble factor(s) remains
unknown. Exogenously introduced C-myc in the miPS cells may
contribute to the transformation since reactivation of C-myc carried
by a retrovirus was considered to be associated with tumor
formation in 20% of chimeric mice [11]. Moreover, leaky
expression of these transgenes may also inhibit complete miPS
cell differentiation and maturation, leading to a greater risk of
immature teratoma formation [28]. However, our results showed
that the transgenes that were used to generate miPS cells were
almost completely silent in miPS-LLCcm cells and spheroid cells
as compared to miPS cells grown on feeder cells and that the two
oncogenes, C-myc and Klf4, were dramatically decreased in the
miPS-LLCcm cells and spheroid cells. This suggests that the
transgenes may not be the main factors responsible for
transformation of the miPS cells in this current model. In addition,
because of no tumor formation was observed in the cases of miPS-
P19c, -B16c, and of no surviving of miPS-LLCc, which were all in
the ‘‘co-culture group’’, there should be little possibility of the
transfer or contribution of mouse tumor viruses in the tumorige-
nicity of miPS cells cultured in the conditioned medium.
Considering the absence of tumorigenicity in these cells in co-
culture group, the non-optimal condition of iPS culture should be
difficult to explain the conversion of miPS cell whereas the
possibility of viral transfection still remains in the cases of miPS-
MC.E12 cm and –MC.E12c [29]. Furthermore, four independent
works report on genomic analyses of iPS and reveal a worrisome
presence of mutations in these cells [30–33], which may be cue
miPS is easier to be affected by the soluble factor(s) existed in
tumor microenvironment. Exosomes are 40–100 nm bilipid
membrane vesicles that are secreted by most cell types. They are
thought to mediate the cell-cell communication and facilitate
biological processes such as cell growth and malignant transfor-
mation [34,35]. Based on the recent reports of tumor exosomes
[36,37], it is worthwhile clarifying the significant role of the
exosomes secreted from LLC cells in the conversion of miPS cells
to CSCs. Moreover, our finding of downregluration of p53 gene
expression in miPS-LLCcm cells indicates that the disturbed p53
network is one of the mechanisms of the conversion of miPS cells
to CSCs. It has been reported that tumor cells can inhibit p53
induction in adjacent fibroblast [38]. It is worthwhile noticing that
a mechanism of this suppression should depend on the factor
secreted from tumor cells, but not on direct cell-to-cell interaction.
Definition and characterization of the genetic alterations and the
secreted factors in the tumor microenvironment, which convert
miPS cells to a CSC will be efficacious for the development of
novel anti-cancer therapies.
The expression of specific cell surface markers has been widely
used to identify CSCs. Some of these surface markers are known to
be common to different CSCs population. However, these markers
may still be associated with normal stem cells [1]. Differentially
expressed surface markers that can distinguish normal stem cells
from CSCs are largely unknown [19]. It is imperative to identify
markers that can distinguish between CSCs and normal stem cells.
This cellular model in this paper should serve as a viable tool to
identify potentially bona fide markers of CSCs. Such markers
could be potential targets in the development of novel therapies
against CSCs without adversely affecting normal stem cell
functions.
Materials and Methods
Cell culture
Mouse induced pluripotent stem cells (miPS; cell name: iPS-
MEF-Ng-20D-17; Lot No. 012) were purchased from Riken Cell
Bank (Japan) and were maintained in medium (DMEM containing
15% FCS, 0.1 mM NEAA, 2 mM L-Glutamine, 0.1 mM 2-
mercaptoethanol, 1000 U/ml LIF, 50 U/ml penicillin and 50 U/
ml streptomycin) on feeder layers of mitomycin-C-treated mouse
embryonic fibroblast (MEF) cells (Reprocell, Japan). Mouse Lewis
lung cancer (LLC) cells were purchased from ATCC (USA) and
were maintained in DMEM containing 10% FCS; mouse
embryonal carcinoma cells (P19) were purchased from Riken Cell
Bank (Japan) and were maintained in aMEM containing 10%
FCS; mouse melanoma cells (B16/BL6) (ATCC, USA) and mouse
mammary tumor cells (BALB-MC.E12) (Riken Cell Bank, Japan)
were maintained in MEM containing 10% FCS.
For preparing conditioned medium (CM) from the different
mouse cancer cell lines, medium was collected from confluent
dishes and filtered using 0.45 mm filter (Millpore, Ireland). Then
3 ml CM were added into 3.5 cm dish overnight to confirm there
were no surviving cancer cells in CM. For the conditioned
medium experiments, miPS cells (without MEF feeder cells) were
maintained in medium described above without LIF. Half of the
medium was changed every day with CM for 4 weeks. miPS cells
without treatment with CM were used as control. For the
coculture experiments, the mouse tumor cell lines were treated
with 0.4 mg/ml mitomycin C (Sigma, USA) and were then used as
feeder cells and cocultured with miPS cells (without MEF feeder
cells) for 4 weeks. miPS cells were passaged every 3 days and cell
morphology was photographed using a Olympus IX81 microscope
equipped with a light fluorescence device (Olympus, Japan).
For primary culture, mouse allografts were cut into small pieces
(approximately 1 mm
3) in HBSS. After washing three times, the
tissues were transferred into a 15 ml tube with 0.25% trypsin of 5–
6 fold volume at 37uC for 40 min. Five microliter DMEM
containing 10% FCS was then added to terminate digestion. The
cellular suspension was then placed into a new tube and
centrifuged at 1000 rpm for 10 min. The cell pellet was
resuspended in 5 ml HBSS, and centrifuged at 1000 rpm for
5 min. The cell pellet was then placed into an appropriate volume
of miPS medium without LIF and the cells were seeded into a dish
at a density of 5610
5/ml. Cells were passaged every 3 days and
cells morphology was observed and photographed using Olympus
IX81 microscope equipped with a light fluorescence device
(Olympus, Japan).
Suspension cultures to generate spheroids were performed as
described in Dontu et al [39]. Briefly, single cells were plated on
non-coated dishes (bacterial culture dish) at a density of 2610
4/ml
in primary culture. Cells were grown in serum-free miPS medium
without LIF. Spheroids cells were collected by gentle centrifuga-
tion (500 rpm) after 7–10 days and dissociated enzymatically
(0.025% trypsin/EDTA).
Animal experiments
Nude mice (Balb/c Slc-nu/nu, female, 6,8 weeks) were
purchased from Charlesriver, Japan. The plan of animal
experiments was reviewed and approved by the ethics committee
for animal experiments of Okayama University under the IDs
OKU-2008211, OKU-2009144, OKU-2010179 and OKU-2011-
305.
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suspended in 100 ml DMEM containing 10% FCS and injected
subcutaneously into nude mice. After 4 weeks, tumors were
excised and fixed in 10% neutral formalin buffer solution (Wako,
Japan).
For micrometastases studies, 1610
5 of miPS-LLCcm spheroid
cells were suspended in 100 ml DMEM containing 10% FCS and
injected into nude mouse tail vein (n=6).
Histologic analysis and immunohistochemistry (IHC)
Tumors were fixed for 24 hours and then processed using a
routine wax-embedding procedure for histologic examination.
Three micrometer thick sections were stained with hematoxylin
and eosin (HE).
IHC for GFP, pan-Cytokeratin, Vimentin, a-Actin, CD31, NF-
M, GFAP was performed using formalin-fixed paraffin embedded
tissue sections and standard procedures. Briefly, 3 mm tissue
sections were deparaffinized and antigen retrieved was performed
using microwave exposure at 95uC for 5 minutes in a citrate buffer
(pH 6.0) or incubation in proteinase K (40 mg/ml) at 37uC for
30 minutes. After hydrogen peroxide blocking and normal serum
blocking (when using mouse monoclonal primary antibody,
M.O.M Mouse Ig Blocking Reagent (Vector, USA) as a blocking
buffer), the sections were then incubated for 2 h at 37uC with the
following primary antibodies: rabbit polyclonal anti-GFP (1:300,
kindly provided by Ayano Satoh, Okayama University, Japan),
mouse monoclonal anti-pan-Cytokeratin (AE1/AE3) (1:200, Santa
Cruz, USA), mouse monoclonal anti-Vimentin (1:200, Santa
Cruz, USA), mouse monoclonal anti-a-Actin (1:200, Santa Cruz,
USA), rat monoclonal anti-CD31 (1:200, Santa Cruz, USA),
mouse monoclonal anti-NF-M (1:50, Santa Cruz, USA), and
mouse monoclonal anti-GFAP (1:200, Santa Cruz, USA). The
sections were then incubated with biotinylated anti-rabbit,
biotinylated anti-rat or biotinylated anti-mouse secondary anti-
body (Vector, USA), followed by incubation with the ABC reagent
(Vector, USA). Detection was accomplished using 3, 30-diamino-
benzidine tetrahydrochloride (DAB, Vector, USA). Incubation of
sections with phosphate-buffered saline (PBS) served as negative
controls. Counter staining were carried out using hematoxylin.
Immunofluorescence
The spheroids were fixed in 10% neutral formalin buffer
solution (Wako, Japan) for 1 hour and washed in PBS. After
centrifugation at 500 rpm during 3 min, the supernatant was
removed carefully with a pipette, and then the spheroids were
counter-stained with hematoxylin during 30 s. After wash in PBS,
spheroids were collected by centrifugation and embedded in OCT
compound, and then 6 mm thich cryosections were cut. Cryosec-
tions were fixed with 10% neutral formalin buffer solution for
15 min at room temperature, and then incubated with block
solution containing 5% BSA, 0.1% Triton X-100 in 0.01 M PBS
at room temperature for 1 hour. Sections were then incubated
with Rabbit anti-Nanog (1:100, Abcam, Japan) or mouse anti-Oct-
3/4 (1:100, Santa Cruz, USA) in blocking solution overnight at
4uC. After three washes in PBS, sections were incubated with Goat
anti-Rabbit secondary antibodies conjugated to Alexa fluoro-
phores 555 or Goat anti-mouse secondary antibodies conjugated
to Alexa fluorophores 488 (1:400, Invitrogen, USA) for 30 min at
room temperature. After three washes in PBS, sections were
mounted with Vectashield (mounting medium for fluorescence
with DAPI, Vector, USA). Images were acquired using an
Olympus IX81 microscope equipped with a light fluorescence
device (Olympus, Japan). Sections where the primary antibodies
were PBS served as negative controls.
RNA extraction, RT-PCR and Quantitative real-time PCR
(RT-qPCR)
Total RNA from cell lines and tumor tissues were isolated by
using RNeasy Mini Kit (QIAGEN, Germany) and TRIzol
(Invitrogen, USA), respectively. One mg of total RNA was then
reverse transcribed using SuperScriptH II Reverse Transcriptase
kit (Invitrogen, USA). RT-PCR was performed for 40 cycles for all
markers, except GAPDH (30 cycles), as follows: denaturing for
2 min at 94uC, annealing for 30 s at 58uC for all primers,
extension at 72uC. PCR products were resolved on a 2% agarose
gel. Primer sequences were as published in Takahashi et al [40],
except Nodal (forward primer, 59 - ATT TGC CAG ACA GAA
GCC AAC - 39, reverse primer, 59- TCC TCC ACA ATC ATG
TCC TTG - 39), Cripto 1 (forward primer, 59 - ATT TGG ACC
CGT TGC TGG GAG AGA - 39, reverse primer, 59 - CAG CTA
GCA TAA AAG TGG TCG TCA - 39) p53 (forward primer, 59 -
ACT CTC CTC CCC TCA ATA AGC - 39, reverse primer, 59 -
TGA TGG TAA GGA TAG GTC GGC - 39), MMP-2 (forward
primer, 59 - CAA GTT CCC CGG CGA TGT C - 39, reverse
primer, 59 - TTC TGG TCA AGG TCA CCT GTC - 39), MMP-
9 (forward primer, 59 - CTG GAC AGC CAG ACA CTA AAG -
39, reverse primer, 59 - CTC GCG GCA AGT CTT CAG AG -
39), and GAPDH (forward primer, 59 - CCC TTC ATT GAC
CTC AAC TAC - 39, reverse primer, 59- CCA CCT TCT TGA
TGT CAT CAT - 39). RT-qPCR was performed with LightCycler
480 SYBR Green I Master (Roche, Germany) according to
manufacturer’s instructions. Signals were detected with Light
Cycler 480 II (Roche, Germany). Amounts of target gene mRNA
were normalized to a reference gene GAPDH. The primer
sequence is same with those of RT-PCR.
Supporting Information
Figure S1 Characterization of miPS cells, miPS-P19 cm
cells, miPS-B16 cm cells, miPS-MC.E12 cm cells and
miPS-MC.E12c cells. (E) Various tissues present in teratomas
derived from miPS cells by HE staining. Scale bars: 100 mm. (F)
Histology of miPS-P19 cm cells, miPS-B16 cm cells, miPS-
MC.E12 cm cells and miPS-MC.E12c cells derived tumors. The
tumors showed malignant phenotype with high nuclear to
cytoplasmic ratio, severe nuclear atypia and multiple pathological
mitotic figures (arrowhead, inset) by HE staining. Scale bars:
100 mm.
(TIFF)
Figure S2 IHC of GFP expression. miPS cell derived
teratoma and miPS-LLCcm cell derived tumor were sectioned
and stained with anti-GFP antibody (Rabbit polyclonal antibody,
brown). Cells were counterstained with hematoxylin. IHC
staining, Scale bars: 100 mm.
(TIFF)
Materials and Methods S1
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Table S1 Genes differentially expressed in miPS-
LLCcm cells versus miPS cells.
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